| Opportunity ID: |
327566 |
| Opportunity Number: |
NOT-CA-20-066 |
| Opportunity Title: |
Notice of Intent to Publish a Funding Opportunity Announcement for Serological Sciences Centers of Excellence |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Cooperative Agreement |
| Category of Funding Activity: |
Health |
| Category Explanation: |
|
| CFDA Number(s): |
|
| Eligible Applicants: |
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Small businesses |
| Additional Information on Eligibility: |
|
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Jun 08, 2020 |
| Last Updated Date: |
Jun 08, 2020 |
| Estimated Synopsis Post Date: |
Jun 10, 2020 |
| Fiscal Year: |
2020 |
| Award Ceiling: |
$1,500,000 |
| Award Floor: |
|
| Estimated Total Program Funding: |
$19,000,000 |
| Expected Number of Awards: |
11 |
| Description: |
This Notice is associated with the COVID-19 Supplemental funding through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH “to develop, validate, improve, and implement serological testing and associated technologies.” The National Cancer Institute (NCI) intends to publish a Funding Opportunity Announcement (FOA) as a Request for Applications (RFAs) to solicit applications to establish Serological Sciences Centers of Excellence of collaborating investigators and an RFA for research projects . Specifically, both the Centers and the projects will identify and advance research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection, especially as it relates to cancer patients. The Serological Sciences Centers of Excellence and research projects will be components of the Serological Sciences Network which will be coordinated through the Frederick National Lab for Cancer Research (FNL). Other components of the Network will include the FNL Serology Lab and Serological Capacity Building Centers. It may also include SBIR grants and other grants and contracts related to serology associated with SARS-CoV-2. This Notice is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations. The FOAs are expected to be published in June 2020 with expected application due dates in July 2020. The FOAs will use the U54 and U01 activity codes (Clinical Trial Not Allowed). Details of the planned FOAs are provided below. |
| Version: |
1 |
|
